Earnings ·
Faeth Therapeutics reports Q3 net loss of $0.79 per share as cash rises to $174.8 million
FTHFaeth Therapeutics, Inc.
Faeth Therapeutics reported a third-quarter net loss of $20.4 million, or $0.79 per diluted share, compared with a $4.6 million loss in the prior-year period. Research and development expenses increased to $11.7 million from $2.5 million, driven by clinical trial and personnel costs for its lead program PIKTOR. General and administrative expenses rose to $10.4 million from $2.3 million due to higher legal fees and staffing. The company ended the quarter with $174.8 million in cash, cash equivalents, and marketable securities, up significantly from $21.2 million at year-end 2025. Faeth also announced that the FDA granted Fast Track designation for PIKTOR plus paclitaxel in advanced endometrial cancer and highlighted preclinical data presented at ESMO 2026. The company is a clinical-stage biotechnology firm developing multi-node oncology therapies.